VALYSTR · Stock research
Listed on NasdaqGM. What the market is pricing into ADMA Biologics, Inc. (ADMA) in the Healthcare sector: implied growth, valuation scenarios, SEC-filed financials, and what has moved the stock.
Healthcare · Biological Products, (No Diagnostic Substances) · market value about $2.5B · P/E 15.9 · revenue $512M (as of 2026-11-04)
Opening the full page… All companies · Research guides · What a reverse DCF shows